Hologic Stock Price, News & Analysis (NASDAQ:HOLX)

$38.87 -0.42 (-1.07 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$38.87
Today's Range$38.74 - $39.30
52-Week Range$35.33 - $46.80
Volume1.41 million shs
Average Volume2.91 million shs
Market Capitalization$10.86 billion
P/E Ratio10.33
Dividend YieldN/A
Beta0.77

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:HOLX
CUSIP43644010
Phone508-263-2900

Debt

Debt-to-Equity Ratio0.87%
Current Ratio1.25%
Quick Ratio0.98%

Price-To-Earnings

Trailing P/E Ratio10.3272040295621
Forward P/E Ratio17.28
P/E Growth1.77

Sales & Book Value

Annual Sales$3.06 billion
Price / Sales3.51
Cash Flow$3.63 per share
Price / Cash10.72
Book Value$11.55 per share
Price / Book3.37

Profitability

Trailing EPS$3.79
Net Income$755.50 million
Net Margins34.53%
Return on Equity20.07%
Return on Assets7.11%

Miscellaneous

Employees6,233
Outstanding Shares276,530,000

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) issued its earnings results on Thursday, February, 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The medical equipment provider earned $791.10 million during the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share. View Hologic's Earnings History.

When will Hologic make its next earnings announcement?

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its second quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $0.53-0.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.55. The company issued revenue guidance of $770-785, compared to the consensus revenue estimate of $790.90 million.

Where is Hologic's stock going? Where will Hologic's stock price be in 2018?

14 analysts have issued twelve-month price objectives for Hologic's shares. Their predictions range from $42.00 to $52.00. On average, they anticipate Hologic's stock price to reach $48.36 in the next twelve months. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • 1. According to Zacks Investment Research, "Hologic posted better-than-expected results in first-quarter fiscal 2018 primarily on strength in the Molecular Diagnostics. Growth across all geographical regions buoys optimism. Breast Health performed well based on differentiated products. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging. On the flip side, the blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. Over the past three months, Hologic has been trading below the broader industry." (2/13/2018)
  • 2. Needham & Company LLC analysts commented, "HOLX’s F1Q18 revenue was consistent with its 1/8/18 preannouncement while its EPS beat consensus. Management reiterated its FY18 revenue guidance and raised its EPS guidance due to tax reform. We note that HOLX expects to reinvest about half of its tax savings in marketing campaigns and R&D. HOLX’s organic revenue growth increased to 4.9% (adjusted for selling days) in F1Q18 from 4.4% in F4Q17. Breast Health growth improved from last quarter driven by the stronger international sales while Diagnostics growth (excluding the Blood divestiture) slowed. We expect HOLX’s revenue growth to accelerate as its Aesthetics business returns to Y/Y growth and it faces easier comps and we reiterate our Buy rating." (2/9/2018)

Are investors shorting Hologic?

Hologic saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 9,708,883 shares, an increase of 21.4% from the January 12th total of 7,998,980 shares. Based on an average trading volume of 2,710,198 shares, the days-to-cover ratio is presently 3.6 days. Currently, 3.5% of the company's stock are sold short.

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • Robert W. McMahon, Chief Financial Officer (Age 49)
  • Peter J. Valenti III, Division President- Breast and Skeletal Health (Age 54)
  • Thomas A. West, Division President- Diagnostics (Age 53)
  • Allison P. Bebo, Senior Vice President - Human Resources (Age 49)
  • Michael J. Watts, Vice President, IR Contact Officer
  • John M. Griffin, General Counsel (Age 57)
  • Sally W. Crawford, Lead Independent Director (Age 64)
  • Elaine S. Ullian, Lead Independent Director (Age 69)
  • Charles J. Dockendorff, Director (Age 63)

Who owns Hologic stock?

Hologic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Parnassus Investments CA (4.93%), Victory Capital Management Inc. (2.14%), Geode Capital Management LLC (1.10%), Two Sigma Advisers LP (1.02%), Alliancebernstein L.P. (0.64%) and Guggenheim Capital LLC (0.60%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Who sold Hologic stock? Who is selling Hologic stock?

Hologic's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., TIAA CREF Investment Management LLC, Macquarie Group Ltd., Bank of Montreal Can, Alliancebernstein L.P., Suntrust Banks Inc., First Trust Advisors LP and State of Wisconsin Investment Board. Company insiders that have sold Hologic company stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was acquired by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Two Sigma Advisers LP, Guggenheim Capital LLC, Assenagon Asset Management S.A., Victory Capital Management Inc., Rock Springs Capital Management LP, Ascend Capital LLC and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $38.87.

How big of a company is Hologic?

Hologic has a market capitalization of $10.86 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $3.79 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]


MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  590 (Vote Outperform)
Underperform Votes:  393 (Vote Underperform)
Total Votes:  983
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hologic (NASDAQ:HOLX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.862.692.69
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.36$48.79$47.54$48.62
Price Target Upside: 28.10% upside11.26% upside21.55% upside24.78% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Canaccord GenuityReiterated RatingBuy$48.00LowView Rating Details
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00HighView Rating Details
2/9/2018Needham & Company LLCReiterated RatingBuy$50.00HighView Rating Details
2/9/2018Stifel NicolausDowngradeBuy -> Hold$45.00 -> $42.00HighView Rating Details
1/19/2018Deutsche BankDowngradeBuy -> Hold$49.00MediumView Rating Details
1/4/2018Bank of AmericaUpgradeNeutral -> Buy$50.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$50.00MediumView Rating Details
12/20/2017CowenUpgradeBuy$52.00LowView Rating Details
12/8/2017Goldman Sachs GroupUpgradeBuy -> Conviction-Buy$45.00 -> $50.00LowView Rating Details
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$49.00 -> $44.00N/AView Rating Details
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 -> $51.00LowView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$0.53N/AView Earnings Details
2/8/2018Q1 2018$0.50$0.55$785.80 million$791.10 millionViewListenView Earnings Details
11/8/2017Q4 2017$0.49$0.50$792.54 million$802.90 millionViewN/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
11/8/2010Q4 2010$0.30$0.30ViewN/AView Earnings Details
8/2/2010Q3 2010$0.29$0.30ViewN/AView Earnings Details
5/3/2010Q2 2010$0.29$0.29ViewN/AView Earnings Details
2/1/2010Q1 2010$0.26$0.29ViewN/AView Earnings Details
11/9/2009Q4 2009$0.26$0.28ViewN/AView Earnings Details
8/3/2009Q3 2009$0.26$0.29ViewN/AView Earnings Details
5/4/2009Q2 2009$0.27$0.29ViewN/AView Earnings Details
2/2/2009Q1 2009$0.30$0.31ViewN/AView Earnings Details
11/11/2008Q4 2008$0.30$0.30ViewN/AView Earnings Details
7/30/2008Q3 2008$0.29$0.33ViewN/AView Earnings Details
5/1/2008Q2 2008$0.28$0.29ViewN/AView Earnings Details
1/31/2008Q1 2008$0.23$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.49$0.52$0.50
Q2 20183$0.51$0.52$0.52
Q3 20183$0.54$0.57$0.56
Q4 20183$0.53$0.60$0.56
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Hologic (NASDAQ:HOLX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.88%
Institutional Ownership Percentage: 95.24%
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Namal NawanaDirectorBuy6,600$37.88$250,008.006,954View SEC Filing  
11/20/2017Karleen Marie ObertonVPSell1,023$39.84$40,756.32View SEC Filing  
11/13/2017Elaine UllianDirectorSell9,282$40.50$375,921.00View SEC Filing  
11/8/2017Karleen Marie ObertonVPSell1,256$39.29$49,348.249,406View SEC Filing  
11/6/2017Karleen Marie ObertonVPSell538$39.40$21,197.208,343View SEC Filing  
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.2423,810View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.7223,810View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.4045,634View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.6223,810View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.2020,994View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.4946,206View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.8043,165View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.5840,577View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.0038,832View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.0437,377View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00157,305View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.6425,839View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.6524,596View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.6023,810View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00152,305View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.4236,798View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.3613,260View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.0510,859View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.889,065View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.669,839View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.6842,898View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.0017,005View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.0067,140View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.8455,053View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.5423,257View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.269,023View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.6031,157View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.808,819View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.5020,983View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.003,914View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.003,914View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.0039,215View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.2039,215View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.8039,215View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.321,500View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00815,306View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00815,306View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.6811,341View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00122View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00815,306View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.0314,470View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00237,500View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00198,900View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.9011,341View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00825,891View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.0019,090View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.4027,749View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00825,891View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.005,052View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.2820,632View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Hologic (NASDAQ HOLX) News Headlines

Source:
DateHeadline
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Boston Scientific, Hologic, ResMed, and Wright MedicalQuotidian Technical Highlights on Selected Medical Equipment Stocks -- Boston Scientific, Hologic, ResMed, and Wright Medical
www.bizjournals.com - February 20 at 8:40 AM
Hologic, Inc. (HOLX) Director Namal Nawana Buys 6,600 SharesHologic, Inc. (HOLX) Director Namal Nawana Buys 6,600 Shares
www.americanbankingnews.com - February 14 at 6:32 PM
Gabelli Analysts Decrease Earnings Estimates for Hologic, Inc. (HOLX)Gabelli Analysts Decrease Earnings Estimates for Hologic, Inc. (HOLX)
www.americanbankingnews.com - February 14 at 11:18 AM
Hologic (HOLX) Upgraded to Buy at Zacks Investment ResearchHologic (HOLX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - February 13 at 5:22 PM
Hologic, Inc. to Post FY2022 Earnings of $3.05 Per Share, Gabelli Forecasts (HOLX)Hologic, Inc. to Post FY2022 Earnings of $3.05 Per Share, Gabelli Forecasts (HOLX)
www.americanbankingnews.com - February 13 at 4:52 PM
Hologic, Inc. (HOLX) Forecasted to Earn FY2018 Earnings of $2.23 Per ShareHologic, Inc. (HOLX) Forecasted to Earn FY2018 Earnings of $2.23 Per Share
www.americanbankingnews.com - February 12 at 6:18 AM
Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Increased by AnalystQ3 2018 EPS Estimates for Hologic, Inc. (HOLX) Increased by Analyst
www.americanbankingnews.com - February 12 at 4:26 AM
 Analysts Anticipate Hologic, Inc. (HOLX) Will Post Quarterly Sales of $791.68 Million Analysts Anticipate Hologic, Inc. (HOLX) Will Post Quarterly Sales of $791.68 Million
www.americanbankingnews.com - February 11 at 2:08 AM
Hologic (HOLX) Cut to "Hold" at Stifel NicolausHologic (HOLX) Cut to "Hold" at Stifel Nicolaus
www.americanbankingnews.com - February 10 at 10:54 PM
Hologic, Inc. (HOLX) Receives Average Rating of "Buy" from AnalystsHologic, Inc. (HOLX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 7:56 AM
Hologic, Inc. (HOLX) Expected to Announce Earnings of $0.52 Per ShareHologic, Inc. (HOLX) Expected to Announce Earnings of $0.52 Per Share
www.americanbankingnews.com - February 9 at 9:10 PM
Hologic (HOLX) Stock Rating Reaffirmed by Canaccord GenuityHologic (HOLX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - February 9 at 8:24 PM
Hologic, Inc. (HOLX) Sees Significant Growth in Short InterestHologic, Inc. (HOLX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 9 at 5:26 PM
Hologic (HOLX) Given "Hold" Rating at Royal Bank of CanadaHologic (HOLX) Given "Hold" Rating at Royal Bank of Canada
www.americanbankingnews.com - February 9 at 3:26 PM
Hologic (HOLX) Stock Rating Reaffirmed by Needham & Company LLCHologic (HOLX) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - February 9 at 1:04 PM
Hologic Inc Q1 Earnings AdvanceHologic Inc Q1 Earnings Advance
www.finanznachrichten.de - February 9 at 9:35 AM
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins DownHologic (HOLX) Q1 Earnings & Revenues Top, Margins Down
www.zacks.com - February 9 at 9:35 AM
Hologic Raises EPS Forecast - Quick FactsHologic Raises EPS Forecast - Quick Facts
www.nasdaq.com - February 9 at 9:35 AM
Hologic Announces Financial Results for First Quarter of Fiscal 2018Hologic Announces Financial Results for First Quarter of Fiscal 2018
finance.yahoo.com - February 9 at 9:35 AM
Hologic beats Street 1Q forecastsHologic beats Street 1Q forecasts
finance.yahoo.com - February 9 at 9:35 AM
Hologic (HOLX) Announces  Earnings Results, Beats Expectations By $0.05 EPSHologic (HOLX) Announces Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - February 8 at 9:28 PM
Hologic (HOLX) Issues Q2 Earnings GuidanceHologic (HOLX) Issues Q2 Earnings Guidance
www.americanbankingnews.com - February 8 at 6:02 PM
CAH vs. HOLX: Which Will Fare Better This Earnings Season?CAH vs. HOLX: Which Will Fare Better This Earnings Season?
www.zacks.com - February 7 at 9:41 AM
Should You Sell Hologic (HOLX) Before Earnings?Should You Sell Hologic (HOLX) Before Earnings?
finance.yahoo.com - February 6 at 9:31 AM
Hologics (HOLX) "Buy" Rating Reiterated at Needham & Company LLCHologic's (HOLX) "Buy" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - February 1 at 8:14 PM
Hologic (HOLX) Set to Announce Quarterly Earnings on ThursdayHologic (HOLX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - February 1 at 1:56 AM
Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00% Convertible Senior Notes Due 2042Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00% Convertible Senior Notes Due 2042
finance.yahoo.com - January 30 at 10:10 AM
Hologic (HOLX) Downgraded to "Strong Sell" at BidaskClubHologic (HOLX) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - January 28 at 8:54 AM
Aptima® HBV Quant Assay for Quantitation of Hepatitis B Viral Load Receives PMA ApprovalAptima® HBV Quant Assay for Quantitation of Hepatitis B Viral Load Receives PMA Approval
finance.yahoo.com - January 25 at 9:36 AM
 Brokerages Expect Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $787.72 Million Brokerages Expect Hologic, Inc. (HOLX) Will Announce Quarterly Sales of $787.72 Million
www.americanbankingnews.com - January 25 at 1:56 AM
Hologics Cynosure Division Launches TempSure™ EnviHologic's Cynosure Division Launches TempSure™ Envi
finance.yahoo.com - January 22 at 12:46 PM
Hologic launches new RF device for aesthetic useHologic launches new RF device for aesthetic use
seekingalpha.com - January 22 at 11:18 AM
Hologic (HOLX) Lowered to Hold at Deutsche BankHologic (HOLX) Lowered to Hold at Deutsche Bank
www.americanbankingnews.com - January 20 at 10:26 PM
Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural ChallengesDeutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges
www.msn.com - January 19 at 12:30 PM
Hologic, Inc. -- Moodys assigns Ba3 rating to Hologics senior unsecured bondsHologic, Inc. -- Moody's assigns Ba3 rating to Hologic's senior unsecured bonds
finance.yahoo.com - January 17 at 11:26 AM
Hologic Announces Pricing of Offering of $1 Billion of Senior NotesHologic Announces Pricing of Offering of $1 Billion of Senior Notes
www.prnewswire.com - January 16 at 10:19 PM
Hologic (HOLX) to Offer $1B of Senior NotesHologic (HOLX) to Offer $1B of Senior Notes
www.streetinsider.com - January 16 at 3:29 PM
Hologic Announces Offering of $1 Billion of Senior NotesHologic Announces Offering of $1 Billion of Senior Notes
finance.yahoo.com - January 16 at 3:29 PM
Hologic (HOLX) to Offer $1B of Senior Notes - StreetInsider.comHologic (HOLX) to Offer $1B of Senior Notes - StreetInsider.com
www.streetinsider.com - January 16 at 11:30 AM
Hologic, Inc. (HOLX) Given Consensus Recommendation of "Buy" by BrokeragesHologic, Inc. (HOLX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 8:00 AM
Hologic (HOLX) Lowered to "Sell" at BidaskClubHologic (HOLX) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - January 13 at 4:52 PM
Hologic (HOLX) Appoints Namal Nawana to BoardHologic (HOLX) Appoints Namal Nawana to Board
www.streetinsider.com - January 13 at 10:59 AM
Namal Nawana Elected to Hologic Board of DirectorsNamal Nawana Elected to Hologic Board of Directors
finance.yahoo.com - January 12 at 10:53 AM
Gabelli Weighs in on Hologic, Inc.s FY2018 Earnings (HOLX)Gabelli Weighs in on Hologic, Inc.'s FY2018 Earnings (HOLX)
www.americanbankingnews.com - January 11 at 3:58 PM
Contrasting Hologic (HOLX) and Illumina (ILMN)Contrasting Hologic (HOLX) and Illumina (ILMN)
www.americanbankingnews.com - January 11 at 3:06 AM
Hologic Sees Q1 Revenue Above Guidance RangeHologic Sees Q1 Revenue Above Guidance Range
www.finanznachrichten.de - January 9 at 3:31 PM
Hologic (HOLX) Reports Prelim. 1Q18 Revenue Above Consensus - StreetInsider.comHologic (HOLX) Reports Prelim. 1Q18 Revenue Above Consensus - StreetInsider.com
www.streetinsider.com - January 9 at 11:10 AM
Hologic (HOLX) Price Target Raised to $50.00Hologic (HOLX) Price Target Raised to $50.00
www.americanbankingnews.com - January 9 at 9:44 AM
Hologic to Announce Financial Results for the First Quarter of Fiscal 2018 on Thursday, February 8, 2018Hologic to Announce Financial Results for the First Quarter of Fiscal 2018 on Thursday, February 8, 2018
finance.yahoo.com - January 8 at 11:00 AM
Hologic Preliminary Revenues Increase 8% to Approximately $791 Million in the First Quarter of Fiscal 2018Hologic Preliminary Revenues Increase 8% to Approximately $791 Million in the First Quarter of Fiscal 2018
finance.yahoo.com - January 8 at 11:00 AM

SEC Filings

Hologic (NASDAQ:HOLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Hologic (NASDAQ HOLX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.